Endostatin effects on tumor cells and vascular network of human renal cell carcinoma implanted on chick embryo chorioallantoic membrane

Anticancer Research

Volumn 35, Issue 12, 2015, Pages 6521-6528

  Ferician, Ovidiu ^a   Cimpean, Anca Maria ^a   Avram, Stefana ^a   Raica, Marius ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chick embryo chorioallantoic membrane; Endostatin; Renal cell carcinoma

Indexed keywords

CD34 ANTIGEN; ENDOGLIN; ENDOSTATIN; KI 67 ANTIGEN; MESSENGER RNA; SMOOTH MUSCLE ACTIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER PROGNOSIS; CANCER RESISTANCE; CAPILLARY DENSITY; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY RESISTANCE; TUMOR CELL; ANIMAL; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; PROGNOSIS;

ANIMALS; CARCINOMA, RENAL CELL; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ENDOSTATINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS;

EID: 84949429899     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jamel A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics 2007. CA Cancer J Clin 57: 43-46, 2007.
2. Rini BI and Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000, 2009.
3. Braga MS, Turaca TL, Foguer K, Chaves KC, Pesquero JB, Chammas R, Schor N and Bellini MH: Vascular endothelial growth factor as a biomarker for endostatin gene therapy. Biomed Pharmacother 67: 511-515, 2013.
4. Guan KP, Xiao ZD, Wang D, Shi HZ, Guan YY, Lu L, Han SJ and Li CL: Clinical significance of serum levels of endostatin in patients with clear cell renal cell carcinoma. Zhonghua Wai Ke Za Zhi 47: 737-739, 2009.
5. Coutinho EL1, Andrade LN, Chammas R, Morganti L, Schor N and Bellini MH: Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma. FASEB J 21: 3153-3161, 2007.
6. Courthod G, Tucci M, Di Maio M and Scagliotti GV: Papillary renal cell carcinoma: A review of the current therapeutic landscape. Crit Rev Oncol Hematol, 2015, in press
7. Fergelot P1, Bernhard JC, Soulet F, Kilarski WW, Leon C, Courtois N, Deminiere C, Herbert JM, Antczak P, Falciani F, Rioux-Leclercq N, Patard JJ, Ferriere JM, Ravaud A, Hagedorn M and Bikfalvi A: The experimental renal cell carcinoma model in the chick embryo. Angiogenesis 16: 181-194, 2013.
8. Chen J, Ruan X, Wang S, Zhang B, Liu B, Sun Z and Liu Q: Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor. Tumour Biol 35: 10993-1003, 2014.
9. Pan X1, Wang Y, Zhang M, Pan W, Qi ZT and Cao GW: Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol 10: 1409-1414, 2004.
10. Ribatti D: The chick embryo chorioallantoic membrane as a model for tumor biology. Exp Cell Res 328: 314-324, 2014.
11. Ribatti D: Chicken chorioallantoic membrane angiogenesis model. Methods Mol Biol 843: 47-57, 2012.
12. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y: RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14: 22-29, 2012.
13. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M and Sukhatme VP:Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189-197, 1999.
14. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R and Olsen BR: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18: 4414-4423, 1999.
15. Mellon MJ, Bae KH, Steding CE, Jimenez JA, Kao C, Gardner TA: Suppression of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene therapy. Hum Gene Ther 19: 487-495, 2008.
16. Bartsch G Jr, Eggert K, Soker S, Bokemeyer C, Hautmann R and Schuch G: Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma. J Urol 179: 326-332, 2008.
17. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S and Yoon SS: Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by upregulation of multiple proangiogenic factors. Clin Cancer Res 14: 1529-1539, 2008.
18. Fujita K, Ujike T, Nagahara A, Uemura M, Tanigawa G, Shimazu K, Fushimi H, Yamaguchi S and Nonomura N: Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy. Int J Urol 22: 463-467, 2015.
19. del Castillo G, Sanchez-Blanco E, Martin-Villar E, Valbuena-Diez AC, Langa C, Perez-Gomez E, Renart J, Bernabeu C and Quintanilla M. Soluble endoglin antagonizes Met signaling in spindle carcinoma cells.Carcinogenesis 36: 212-222, 2015.
20. Saroufim A, Messai Y, Hasmim M, Rioux N, Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone B, Escudier B and Chouaib S: Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer 110: 1778-1784, 2014.
21. Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stoblen F, Lichtenegger W, Sehouli J and Kummel S: Prognostic significance of the angiogenic factors agiogenin, endoglin and endostatin in cervical cancer. Anticancer Res 31: 2651-2655, 2011.
22. Barresi V, Branca G, Caffo M, Caltabiano R, Ieni A, Vitarelli E, Lanzafame S and Tuccari G: Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy? Int J Mol Sci 15: 5663-5679, 2014.
23. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B and Rasmuson T: Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 97: 706-710, 2006.
24. Raica M, Cimpean AM and Anghel A: Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma. Neoplasma 54: 278-284, 2007 .
25. Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP and Rosen LS: An openlabel phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res 20: 5918-5926, 2014.